georgie18
2 월 전
IGC...4138...🥳Off the 3897 Alert...
georgie18
Member Level
Re: None
Wednesday, December 11, 2024 1:17:54 PM
Post#
667553
of 667765
IGC...3897...🥳Scaling in here... New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's
POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.
The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.
"We plan to initiate a new Phase 2 clinical trial for IGC-AD1 in 2025," said Ram Mukunda, CEO of IGC Pharma. "The trial underscores our commitment to advancing IGC-AD1 as a potential disease-modifying therapy for Alzheimer's. Cognitive decline is one of the most devastating aspects of Alzheimer's, severely impacting patients' memory, attention, and reasoning. By focusing on cognitive outcomes and underlying disease mechanisms such as amyloid plaques and tau tangles, we aim to address the critical unmet needs of patients and caregivers. This subsequent research phase is a significant step forward in delivering innovative treatments to those who need them most.
These new trials represent a pivotal step in advancing IGC-AD1 as a transformative Alzheimer's treatment. By exploring its potential as a disease-modifying therapy, we aim to create opportunities for strategic partnerships and licensing with major pharmaceutical companies. Our vision is to deliver innovative therapies that address the immense challenges faced by patients and caregivers while generating substantial value for our investors."
georgie18
2 월 전
IGC...3897...🥳Scaling in here... New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's
POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.
The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.
"We plan to initiate a new Phase 2 clinical trial for IGC-AD1 in 2025," said Ram Mukunda, CEO of IGC Pharma. "The trial underscores our commitment to advancing IGC-AD1 as a potential disease-modifying therapy for Alzheimer's. Cognitive decline is one of the most devastating aspects of Alzheimer's, severely impacting patients' memory, attention, and reasoning. By focusing on cognitive outcomes and underlying disease mechanisms such as amyloid plaques and tau tangles, we aim to address the critical unmet needs of patients and caregivers. This subsequent research phase is a significant step forward in delivering innovative treatments to those who need them most.
These new trials represent a pivotal step in advancing IGC-AD1 as a transformative Alzheimer's treatment. By exploring its potential as a disease-modifying therapy, we aim to create opportunities for strategic partnerships and licensing with major pharmaceutical companies. Our vision is to deliver innovative therapies that address the immense challenges faced by patients and caregivers while generating substantial value for our investors."
Smilin_B
10 월 전
Looks like Bradbury is unleashing some of its shares into the market
On March 22, 2024, the Company entered into a Share Purchase Agreement (the "SPA") with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34. The funds will support general corporate purposes and the Company's advancement of its investigational medicines including IGC-AD1.
The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.
ErnieBilco
10 월 전
– Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation Associated with Dementia Due to Alzheimer’s Disease –
Potomac, MD, March 20, 2024 – IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).
The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential for IGC-AD1.
The study’s primary goal is to assess the change in AAD after six weeks using a standard scale, the Cohen Mansfield Agitation Inventory (“CMAI”). Based on interim data, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared to those on placebo, and the positive effects were observed as early as week two of the trial.
Pennyes
3 년 전
IGC breakout alert and 10% move up, just the ignition to the rally!? Isn't that a spot on "breakout alert" or what?. Well, almost all (more than 90% of my alerts) goes through a spot on results!..
Target price: $1.10, $2 and $5, all these are near term to short term targets spanning days, weeks to just couple of months!.
Pennyes
3 년 전
Agree with your second half, scammer CEO, but the company came long way now, he seems to be still on top of the management, but sales, products and research pipelines using cannabis/cbd are progressing, hard to believe but it is happening!.
the stupid stock price and poor performance is a industry/or Sector wide manipulation, nothing to do with how this co managed etc!.
and that is going to change now, as the sector reached a boiling point of exploding out of this manipulators control!, and every stock, good, bad, ugly will skyrocket...
you can take it or leave it, that is destined to happen!.
Enjoy the ride!
Pennyes
3 년 전
Notorious "inverted Cup & Handle" is coming to an End!....IGC juar Bottomed!.
and that's got to change the status of IGC trading and performance, cannot imagine how notoriously manipulated all the cannabis/hemp related stocks!, but there is always a limit to what they can do and a Breakout out will smash and toast the MMs, shorties and everyone else is screwing up this stock...and the time is Now!..
Enjoy the ride, in my next post I will provide target prices, it will be juicy and nice!.
Hot Features
프리미엄
실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Dennis14
1 일 전
TheFinalCD
5 월 전
TrendTrade2016
10 월 전
gail
10 월 전
Porterhouse10
3 년 전
geocam
4 년 전
